H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Ampliphi Biosciences (APHB) today and set a price target of $3.50. The company’s shares closed yesterday at $0.31, close to its 52-week low of $0.15.
Pantginis said:
“Valuation and risks to price target achievement. We maintain our Buy rating and price target of $3.50. We project the following in our clinical NPV model for S. aureus: (1) projected launch in 2021 for bacteremia with a 15% chance of success and $300 million in peak sales; and (2) projected launch in 2022 for prosthetic joint infections with a 10% chance of success and $200 million in peak sales.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -14.0% and a 30.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ampliphi Biosciences with a $3.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.37 and a one-year low of $0.15. Currently, Ampliphi Biosciences has an average volume of 464K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.
